Diazoxide choline controlled release - Essentialis

Drug Profile

Diazoxide choline controlled release - Essentialis

Alternative Names: DCCR - Essentialis; Diazoxide choline; Diazoxide choline controlled release

Latest Information Update: 10 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Essentialis
  • Class Antihypertensives; Antihypoglycaemics; Benzothiadiazines; Diagnostic agents; Peripheral vasodilators; Small molecules
  • Mechanism of Action Potassium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Prader-Willi syndrome
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Prader-Willi syndrome
  • No development reported Hypertriglyceridaemia
  • Discontinued Hypoglycaemia; Obesity

Most Recent Events

  • 05 Jul 2017 Soleno Therapeutics plans a phase III trial for Prader-Willi syndrome in USA at the end of 2017
  • 08 Mar 2017 Essentialis has merged with and became a subsidiary of Capnia
  • 27 Dec 2016 Essentialis plans a phase II/III trial for Prader-Willi syndrome in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top